Asgard Therapeutics

Asgard Therapeutics, a Swedish biotech company founded in 2018, is at the forefront of cancer immunotherapy research through direct cell reprogramming technologies. The company's proprietary TrojanDC technology, originating from Lund University, aims to initiate immune responses by leveraging professional antigen presenting cells' biological properties. With a focus on personalized cancer immunotherapies, Asgard Therapeutics has secured a significant €30.00M Series A investment on 14th March 2024, with backing from prominent investors including Novo Holdings, Industrifonden, RV Invest, Boehringer Ingelheim Venture Fund, and Johnson & Johnson Innovation – JJDC. Operating in the biotechnology and health and wellness industries, the company's slogan, "Exploring reprogramming as the next leap forward in cancer immunotherapy," encapsulates its pioneering spirit and commitment to advancing treatment possibilities. Asgard Therapeutics' headquarters in Sweden positions it within a strong biotech ecosystem and reflects its Scandinavian roots.